Resident Rounds Part II: Injectables

January 2017 | Volume 16 | Issue 1 | Features | 80 | Copyright © January 2017


Mona D. Mislankar MD, Rajiv K. Nathoo MD, and Sailesh Konda MD

Department of Dermatology, University of Florida College of Medicine, Gainesville, FL

Table 2Table 3

DISCLOSURES

The authors have no conflicts of interest to declare.

REFERENCES

  1. Beer K, Downie J, Beer J. A treatment protocol for vascular occlusion from particulate soft tissue augmentation. J Clin Aesthet Dermatol. 2012;5:44-47. 
  2. Dayan SH, Arkins JP, Mathison CC. Management of impending necrosis associated with soft tissue ller injections. J Drugs Der- matol. 2011;10:1007-1012. 
  3. Delaere L, Zeyen T, Foets B, Van Calster J, Stalmans I. Allergic reaction to hyaluronidase after retrobulbar anaesthesia: a case series and review. Int Ophthalmol. 2009;29:521-528. 
  4. Dermal llers. Available at: http://emedicine.medscape.com/ article/1125066-overview. Accessed December 11, 2016. 
  5. Jones DH, Kenkel JM, Fagien S, et al. Proper technique for ad- ministration of ATX-101 (deoxycholic acid injection): Insights from an injection practicum and roundtable discussion. Dermatol Surg. 2016;42(suppl 1):s275-s281. 
  6. Kedlaya D. Botulinum toxin: Overview. Available at: http://emedi- cine.medscape.com/article/325451-overview. Accessed Decem- ber 11, 2016. 
  7. Scheinfeld N. The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face. Der- matol Online J. 2005;11:9. 
  8. Tholpady A. Collagen and other injectable llers treatment and management. Available at: http://emedicine.medscape.com/ article/1271282-treatment. Accessed December 11, 2016. 

AUTHOR CORRESPONDENCE

Mona Mislankar MD mmislankar@u .edu
Close Menu